PMID- 29254376
OWN - NLM
STAT- MEDLINE
DCOM- 20190916
LR  - 20190916
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 34
IP  - 5
DP  - 2018 May
TI  - Mirabegron improves quality-of-life, treatment satisfaction, and persistence in 
      patients with overactive bladder: a multi-center, non-interventional, real-world, 
      12-month study.
PG  - 785-793
LID - 10.1080/03007995.2017.1419170 [doi]
AB  - OBJECTIVE: Observational studies can provide evidence about patient outcomes in 
      routine clinical practice. This prospective, non-interventional study (BELIEVE) 
      is the largest real-world European study to date to assess quality-of-life, 
      treatment satisfaction, resource utilization, and persistence in patients with 
      overactive bladder (OAB) who were prescribed mirabegron as part of routine 
      clinical practice. METHODS: The primary objective was to evaluate change from 
      baseline in quality-of-life based on overactive bladder questionnaire (OAB-q) 
      sub-scales. Secondary objectives included evaluation of treatment persistence, 
      patient satisfaction, healthcare resource utilization and adverse events (AEs). 
      Follow-up was for 12 months with visit windows at 2-4 and 10-12 months. Median 
      change from baseline in total OAB-q and its sub-scales (Health-related 
      quality-of-life [HRQoL] and symptom bother scale) were assessed. RESULTS: 
      Overall, 862 patients were enrolled from eight European countries. In the Full 
      Analysis Set (FAS), 73.7% were female, mean age was 61.2 years; 47.7% >/=65 years. 
      At baseline, 41.3% had switched from other OAB treatments, 42.2% were treatment 
      naive, 10.1% were lapsed, and 6.4% were on combination treatment. Symptom bother 
      and HRQoL total scores improved from baseline to 2-4 and 10-12 months. There was 
      a notable improvement in dry rate, increasing from 34.9% at baseline to 43.7% at 
      10-12 months in the FAS, and a reduction in pad use. Persistence was high, with 
      53.8% of FAS patients remaining on mirabegron at 10-12 months. Overall, no 
      unexpected safety issues were observed and AEs were consistent with the known 
      safety profile of mirabegron. CONCLUSION: Patients receiving mirabegron in a 
      real-world setting reported meaningful improvements in QoL and health status, 
      with a persistence rate of 53.8% at 12 months for the FAS. No unexpected safety 
      issues were observed, and AEs were consistent with the known safety profile of 
      mirabegron.
FAU - Freeman, Robert
AU  - Freeman R
AD  - a Derriford Hospital , Plymouth , Devon , UK.
FAU - Foley, Steve
AU  - Foley S
AD  - b Royal Berkshire Hospital , Reading , Berkshire UK.
FAU - Rosa Arias, Jose
AU  - Rosa Arias J
AD  - c Department of Urology , Hospital Comarcal Santiago Apostol , Miranda de 
      Ebro-Burgos , Spain.
FAU - Vicente, Eduardo
AU  - Vicente E
AD  - d Urology Department , Parc Tauli University Hospital , Sabadell, Barcelona , 
      Spain.
FAU - Grill, Robert
AU  - Grill R
AD  - e Charles University , Prague , Czech Republic.
FAU - Kachlirova, Zuzana
AU  - Kachlirova Z
AD  - e Charles University , Prague , Czech Republic.
FAU - Stari, Anny
AU  - Stari A
AD  - f Astellas Pharma Europe Ltd , Chertsey , Surrey UK.
FAU - Huang, Moses
AU  - Huang M
AD  - f Astellas Pharma Europe Ltd , Chertsey , Surrey UK.
FAU - Choudhury, Nurul
AU  - Choudhury N
AD  - f Astellas Pharma Europe Ltd , Chertsey , Surrey UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT02320773
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180110
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Acetanilides)
RN  - 0 (Thiazoles)
RN  - MVR3JL3B2V (mirabegron)
SB  - IM
MH  - Acetanilides/*therapeutic use
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction/*statistics & numerical data
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Thiazoles/*therapeutic use
MH  - *Urinary Bladder, Overactive/drug therapy/epidemiology/psychology
OTO - NOTNLM
OT  - Mirabegron
OT  - overactive bladder
OT  - persistence
EDAT- 2017/12/20 06:00
MHDA- 2019/09/17 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2019/09/17 06:00 [medline]
PHST- 2017/12/20 06:00 [entrez]
AID - 10.1080/03007995.2017.1419170 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2018 May;34(5):785-793. doi: 10.1080/03007995.2017.1419170. 
      Epub 2018 Jan 10.